MA-PTC
PTC (NASDAQ: PTC) today announced the release of its 2019 “State of Industrial Innovation” report series. The series provides an ongoing review and analysis of the industrial augmented reality (AR) and industrial internet of things (IIoT) markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190508005784/en/
Among the findings included in the latest “State of Industrial Augmented Reality ” report: AR adoption has become focused on delivering enhanced methods of instruction, guidance, and training for front-line workers, enabling the workforce optimization necessary to address the growing skilled labor shortage the industrial sector faces. According to the “State of the Industrial Internet of Things ” report: IIoT is poised to have a breakout year in 2019 as companies seek to improve operational effectiveness, reduce costs, and decrease risk inherent in the modern competitive landscape. Both reports explore the breadth of the increasingly multifaceted opportunities presented by these markets.
“Organizations in industrial settings realize the urgency in improving productivity and streamlining operations to remain competitive and relevant,” said Jim Heppelmann, president and CEO, PTC. “The insights offered in these reports validate that the adoption of industrial AR and IIoT is an important step toward achieving these goals.”
Highlights from the Report Findings:
The State of Industrial Augmented Reality
- Industrial enterprises are the highest adopters of augmented reality, comprising nearly 60% of the survey responses, with efforts focused on improving worker performance and solving the skilled labor shortage faced by companies worldwide.
- 55% of use cases aimed at improving worker productivity focus on delivering instructions and guidance primarily within manufacturing, service, and training environments.
- Successful pilots are being moved to production within 12 months at a 20% higher rate, year-over-year, allowing early-movers to capitalize on the competitive advantage.
The State of the Industrial Internet of Things
- IoT is becoming commonplace in heavy-industrial environments, with applications expanding across discrete manufacturing in industrial factories representing over 70% of the survey responses.
- Comprehensive, pre-built IIoT solutions are driving more established use cases, such as operational intelligence (31% of total use cases), as well as emerging use cases, such as predictive maintenance (12%) across manufacturing, operations, and service functions.
- Data processing at the device or “edge-layer” (present in 68% of use cases) is a critical capability for solution providers and there are increasing requirements for the same capabilities at the IoT Gateway (37%) and Cloud (34%) layers.
- Industrial enterprises facing global pressures are seeing the need to quickly deploy IIoT to improve operational effectiveness. 89% of respondents to the 2018 IIoT survey are planning to move to production in the next year, up 6% from 2017.
Leveraging PTC’s 30+ years of technology experience and incorporating data from a cross-section of over 30,000 PTC global customers and 1,000 PTC technology and service partners, PTC’s “State of Industrial Innovation” report series provides a comprehensive view of actionable insights and trends across the industrial ecosystem. To learn more about how industrial AR and IIoT can improve workforce optimization and operational effectiveness, download the “State of Industrial Augmented Reality ” and the “State of the Industrial Internet of Things ” 2019 reports.
Additional Resources
- Blog: State of Industrial Augmented Reality 2019 Report Highlights Use Cases in Industrial Enterprises
- Blog: State of Industrial Internet of Things 2019 Report Identifies Key Use Cases Driving Operational Effectiveness
- Harvard Business Review: “Why Every Organization Needs an AR Strategy ,” authored by PTC CEO Jim Heppelmann and Harvard Professor Michael Porter
About PTC (NASDAQ: PTC)
PTC unleashes industrial innovation
with award-winning, market-proven solutions that enable companies to
differentiate their products and services, improve operational
excellence, and increase workforce productivity. With PTC, and its
partner ecosystem, manufacturers can capitalize on the promise of
today’s new technology to drive digital transformation.
PTC, the State of Industrial Innovation series, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005784/en/
Contact:
PTC Corporate Communications Jack McAvoy jmcavoy@ptc.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom